Tests one dose of ayahuasca in adults with non-epileptic seizures
Tests a single dose of ayahuasca in adults with psychogenic non-epileptic seizures.
Plain-language title generated from the registry record
Registry title: Effects of a Sigle Dose of Ayahuasca in Patients With Psychogenic Non-epileptic Seizures: an Open Label Clinical Trial
Key facts
- Where
- Ribeirão Preto, BrazilSee the site
- Phase
- Phase 1/2
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 60 years old?
Source: NCT07747324, who can take part
Where in Brazil
- Ribeirão Preto Medical SchoolRibeirão Preto, BrazilTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- University of Sao Paulo
- Trial code
- NCT07747324
- Record updated
- 5 August 2026
- Original description
Open label intervention with a single dose of ayahuasca in patients with psychogenic non-epileptic seizures (PNES)Read full original descriptionShow less
Effects of a Sigle Dose of Ayahuasca in Patients With Psychogenic Non-epileptic Seizures: an Open Label Clinical Trial
Open label intervention with a single dose of ayahuasca in patients with psychogenic non-epileptic seizures (PNES)
Inclusion: Patients aged 18 to 60 with documented PNES (confirmed via VEEG), without a diagnosis of comorbid epilepsy, and currently receiving follow-up care at outpatient clinics. To enroll in the study, patients must undergo a gradual reduction and discontinuation of any psychotropic medications (antidepressants, antipsychotics, benzodiazepines, or mood stabilizers/anticonvulsants) they are currently taking, in order to avoid drug interactions with-or influence on-the effects of ayahuasca.
Exclusion: Patients who have not experienced psychogenic seizures in the last 3 months; patients diagnosed with epilepsy; patients who refuse to reduce or discontinue their current psychotropic medications; patients with a history of prior ayahuasca use; patients with a history of substance use disorder; patients who refuse to sign the Informed Consent Form; patients with schizophrenia or other psychotic disorders and/or impaired reality testing; and pregnant or breastfeeding women.